Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

Lu Yang(West China Medical Center of Sichuan University), Youyou Zhang(University of Pennsylvania), Weiwei Shan(Obstetrics and Gynecology Hospital of Fudan University), Zhongyi Hu(University of Pennsylvania), Jiao Yuan(University of Pennsylvania), Jingjiang Pi(University of Pennsylvania), Yueying Wang(University of Pennsylvania), Lingling Fan(Obstetrics and Gynecology Hospital of Fudan University), Zhaoqing Tang(University of Pennsylvania), Chunsheng Li(University of Pennsylvania), Xiaowen Hu(University of Pennsylvania), János L. Tanyi(University of Pennsylvania), Yi Fan(University of Pennsylvania), Qihong Huang(The Wistar Institute), Kathleen T. Montone(University of Pennsylvania), Chi V. Dang(University of Pennsylvania), Lin Zhang(University of Pennsylvania)
Science Translational Medicine
July 26, 2017
Cited by 242

Abstract

gene was focally amplified across 20 types of common cancers. Combination with BETi could greatly expand the utility of PARP inhibition to patients with HR-proficient cancer.


Related Papers

No related papers found

Powered by citation graph analysis